Tanguy Lim-Seiwert
Section of Hematology / Oncology
Assistant Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730

Training

DegreeYearInstitutionArea
MD1999Johannes Gutenberg University 
Residency2000Duke University 
Fellowship2007The University of ChicagoHematology/Oncology

Academic Interests

Dr. Seiwert studies the biology of head and neck cancer and lung cancer, and uses novel, targeted therapies to develop improved treatment strategies for these diseases. He focuses on agents that disrupt specific pathways vital to cancer growth, survival, and metastasis (e.g. c-MET, EGFR, HSP27,…). He employs laboratory models in order to learn how to best use such treatments – e.g. which agents appear promising in certain tumors, identify tumors more likely to respond to certain treatments due to mutations/amplification/etc., and how to best combine treatments with other treatments (radiotherapy, chemotherapy, or other targeted therapies). Dr. Seiwert uses this preclinical knowledge to develop new or improved rational treatments for use in clinical trials to ultimately improve patient care


Clinical Interests

Head and Neck Cancer, implementation of novel treatments in clinical trials, Lung Cancer, concurrent chemotherapy and radiation


Representative Publications

  1. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer.Nat Clin Pract Oncol. 2007 Mar;4(3):156-71.
  2. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm--general principles.Nat Clin Pract Oncol. 2007 Feb;4(2):86-100.
  3. Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):515-22.
  4. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.Nat Clin Pract Oncol. 2006 Jan;3(1):50-7;
  5. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 1;66(1):352-61.



More Information

For more information about Dr. Tanguy Lim-Seiwert publications and research collaborations , please click here